Supportive management of patients with brain tumors

References

• Kaal Evert CA, Vecht CJ. The management of brain edema in brain tumors. Curr. Opin. Oncol.16, 593–600 (2004).
   PubMedGoogle Scholar
• Davies DC. Blood–brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat.200, 639–646 (2002).
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience129, 1011–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Bedford RF, Morris L, Jane JA. Intracranial hypertension during surgery for supratentorial tumor: correlation with preoperative computed tomography scans. Anesth. Analg.61, 430–433 (1982).
   PubMed Web of Science ®Google Scholar
• Fadul C, Wood J, Thaler H, Galicich J, Patterson RH, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology38, 1374–1379 (1988).
   PubMed Web of Science ®Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood–brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery42(5), 1083–1099 (1998).
   PubMed Web of Science ®Google Scholar
• Gomes J, Stevens R, Lewin III J, Mirski M, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit. Care Med.33(6) 1214–1224 (2005).
   PubMed Web of Science ®Google Scholar
• Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. Am. J. Neuroradiol.27, 402–408 (2006).
   PubMedGoogle Scholar
• Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J. Neurol. Neurosurg. Psychiatr.75, 1632–1635 (2004).
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, Kesari S, Drappatz J, Gigas D, Doherty, L. Medical management of patients with brain tumors. J. Neurooncol.80(3), 313–332 (2006).
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteroporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum.44(7), 1496–1503 (2001).
   PubMed Web of Science ®Google Scholar
• Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons – 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med.137, 435–478 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int. J. Rad. Onc. Biol. Phys.62(5), 1423–1426 (2005).
   PubMed Web of Science ®Google Scholar
• DaSilva AN, Schiff D. Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. Surg. Neurol.67, 508–510 (2007).
   PubMedGoogle Scholar
• Sur P, Sribnick E, Patel S, Ray S, Banik N. Dexamethasone decreases temozolomide-induced apoptosis in human glioblastoma T98G cells. Glia50, 160–167 (2005)
   PubMed Web of Science ®Google Scholar
• Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med. Wkly132(29–30), 425–426 (2002).
   PubMedGoogle Scholar
• Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann. Pharmachother.30(5), 520–526 (1996).
   PubMedGoogle Scholar
• Carr L, Mechtler L, Recht L. The effect of corticorelin acetate on peritumoral brain edema: An interim report of an open-label study as part of a Phase III program. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18S), 9095 (2007).
   Google Scholar
• Batchelor T, Sorenson AG, di Tomaso E. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95, (2007).
   PubMed Web of Science ®Google Scholar
• Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology66, 1258–1260 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Kumar A, Conrad C, Levin V. Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiat. Oncol. Biol. Phys.67(2), 323–326 (2007).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment inpatients with cancer and venous thrombosis. Blood100(10), 3484–3488 (2002).
   PubMed Web of Science ®Google Scholar
• Heit J. Cancer and venous thromboembolism: the scope of the problem. Cancer Control12, S1 (2005).
   Google Scholar
• Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data. Medicine (Baltimore)78(5), 285–291 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr. Opin. Pulm. Med.7, 326–331 (2001).
   PubMedGoogle Scholar
• Marras LC, Geerts W, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer89(3), 640–646 (2000).
   PubMed Web of Science ®Google Scholar
• Gerber D, Grossman S, Streiff M. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J. Clin. Oncol.24, 1310–1318 (2006).
   PubMed Web of Science ®Google Scholar
• Semrad TJ, O’Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J. Neurosurg.106(4), 601–608 (2007).
   PubMed Web of Science ®Google Scholar
• Roderick P, Ferris G, Wilson K. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran, and regional anesthesia as thromboprophylaxis. Health Technol. Assess.9(49), 1–78 (2005).
   Google Scholar
• Cerrato D, Ariano C, Fiacchino F. Deep venous thrombosis and low dose heparin prophylaxis in neurosurgical patients. J. Neurosurg.49(3), 378–381 (1978).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Piovella F, Buoncristiani P et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N. Engl. J. Med.339, 80–85 (1998).
   PubMed Web of Science ®Google Scholar
• Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch. Intern. Med.160(15), 2327–2332 (2000).
   PubMed Web of Science ®Google Scholar
• Rogers FB, Cipolle M, Velmahos G, Rozycki G, Luchette F. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines workgroup. J. Trauma53(1), 142–164 (2002).
   PubMedGoogle Scholar
• Geerts W. Prevention of venous thromboembolism in high risk patients. Hematology Am. Soc. Hematol. Educ. Program462–466 (2006).
   PubMedGoogle Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest126(Suppl. 3), S338–S400 (2004).
   PubMedGoogle Scholar
• Goldhaber S, Dunn K, Gerhard-Herman M, Park J, Black P. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest122, 1933–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Lee AY. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Curr. Opin. Pulm. Med.9, 351–355 (2003).
   PubMedGoogle Scholar
• Macdonald R, Amidei C, Baron J et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg. Neurol.59, 363–374 (2003).
   PubMedGoogle Scholar
• Sherman DG, Albers GW, Bladin C et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischemic stroke (PREVAIL Study): an open-label randomized comparison. Lancet369, 1347–1355 (2007).
   PubMed Web of Science ®Google Scholar
• Klerk C, Smorenburg S, Otten H et al. The effect of low molecular weight heparin on survival inpatients with advanced malignancy. J. Clin. Oncol.23, 2130–2135 (2005).
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Fontana F, Marras C et al.In vitro study of low molecular weight heparin effect on cell growth and cell invasion inprimary cell cultures of high-grade gliomas. Oncol. Res.16(5), 245–250 (2006).
   PubMedGoogle Scholar
• Lee AY, Rickles FR, Julian JA. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol.23, 2123–2129 (2005).
   PubMed Web of Science ®Google Scholar
• Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost.5(4), 729–737 (2007).
   PubMed Web of Science ®Google Scholar
• North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB. Phenytoin and postoperative epilepsy. A double-blind study. J. Neurosurg.58(5), 672–677 (1983).
   PubMedGoogle Scholar
• Lee AY, Levine MN, Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349, 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Monreal M, Zacharski L, Jimenez JA, Roncaless J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J. Thromb. Haemost.2, 1311–1315 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valche J et al. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch. Intern. Med.162, 1729–1735 (2002).
   PubMed Web of Science ®Google Scholar
• Perry JR, Rogers L, Laperriere N et al. PRODIGE: a Phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin in patients with newly diagnosed malignant glioma. J. Clin. Oncol.25(Suppl. 18), 2011 (2007).
   Google Scholar
• Hildebrand J, Lecaille C, Perennes J, Delattre J. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology65, 212–215 (2005).
   PubMedGoogle Scholar
• Van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol.6, 423–430 (2007).
   Google Scholar
• Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology46(4), 985–991 (1996).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis inpatients withnewly diagnosed brain tumors: Report of the Quality Standards Sucommittee of the American Academy of Neurology. Neurology54(10), 1886–1893 (2000).
   PubMed Web of Science ®Google Scholar
• Sander J. The use of antiepileptic drugs – principles and practice. Epilepsia45(Suppl. 6), 28–34 (2004).
   PubMed Web of Science ®Google Scholar
• Sirven JI, Wingerchuk DM, DrazkowskiJF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin. Proc.79(12), 1489–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Brouwers MC, Chambers A, Perry J. Can surveying practitioners about their practices help identify priority clinical practice guideline topics? BMC Health Serv. Res.3, 23 (2003).
   PubMedGoogle Scholar
• Siomin V, Angelov L, Li L, Vogelbaum M. Results of a survey of neurosurgical practice patterns regarding prophylactic use of anti-epilepsy drugs in patients with brain tumors. J. Neurooncol.74(2), 211–215 (2005).
   PubMed Web of Science ®Google Scholar
• Taillibert S, Delattre J. Palliative care in patients with brain metastases. Curr. Opin. Oncol.17, 588–592 (2005).
   PubMedGoogle Scholar
• Manaka S, Ishijima B, Mayanagi Y. Postoperative seizures: epidemiology, pathology, and prophylaxis. Neurol. Med. Chir. (Tokyo)43, 589–600 (2003).
   PubMed Web of Science ®Google Scholar
• North JB, Penhall RK, Hanieh A, Hann CS, Challen RG, Frewin DB. Posoperative epilepsy: a double-blind trial of phenytoin after craniotomy. Lancet1(8165), 384–386 (1980).
   PubMedGoogle Scholar
• Mahaley MS, Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg. Neurol.16(6), 399–401 (1981).
   PubMedGoogle Scholar
• Shaw MDM, Foy PM. Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper. J. R. Soc. Med.84, 221–223 (1991).
   PubMed Web of Science ®Google Scholar
• Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure5(4), 291–298 (1996).
   PubMedGoogle Scholar
• Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenité DG et al. Comparative double blind clinical trial of pheytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J. Neurol. Neurosurg. Psychiatr.67(4), 474–480 (1999).
   PubMed Web of Science ®Google Scholar
• DeSantis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia43(2), 175–182, (2002).
   PubMedGoogle Scholar
• Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch. Neurol.63(12), 1746–1749 (2006).
   PubMedGoogle Scholar
• DeAngelis LM. Brain tumors. N. Engl. J. Med.344(2), 114–123 (2001).
   PubMed Web of Science ®Google Scholar
• Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res.41(2), 107–139 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor LP, Posner JB. Phenobarbital rheumatism in patient with brain tumor. Ann. Neurol.25(1), 92–94 (1989).
   PubMed Web of Science ®Google Scholar
• Micali G, Linthicum K, Han N, West DP. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy19(2) 223–227 (1999).
   PubMed Web of Science ®Google Scholar
• Murry D, Cherrick I, Salama V et al. Influence of phenytoinon the disposition of irinotecan: a case report. Am. J. Pediatr. Hematol. Oncol.24(2), 130–133 (2002).
   Google Scholar
• Van den Bent MJ. The role of chemotherapy in brain metastases. Eur. J. Cancer39, 2114–2120 (2003).
   PubMed Web of Science ®Google Scholar
• Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol.72(3), 255–260 (2005).
   PubMed Web of Science ®Google Scholar
• Wen P, Marks P. Medical management of patients with brain tumors. Curr. Opin. Oncol.14, 299–307 (2002).
   PubMedGoogle Scholar
• Kikuchi K, McCormick CI, Neuwelt EA. Immunosuppression by phenytoin: implication for altered immune competence in brain-tumor patients. J. Neurosurg.61(6), 1085–1090 (1984).
   PubMedGoogle Scholar
• Suwanwela N, Phanthumchinda K, Kaoropthum S. Headache in brain tumor: a cross-sectional study. Headache34(7), 435–438 (1994).
   PubMedGoogle Scholar
• Forsyth PA, Posner JB. Headache in patients with brain tumors: a study of 111 patients. Neurology43(9), 1678–1683 (1993).
   PubMed Web of Science ®Google Scholar
• Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications– review and recommendations based on risk assessment. Aliment Pharmacol. Ther.19(10), 1051–1061 (2004).
   PubMed Web of Science ®Google Scholar
• Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of anti-inflammatory drugs. Ann. Intern. Med.114, 735–740 (1991).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoetins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J. Natl Cancer Inst.98, 708–714 (2006).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G et al. Erythropoetin for patients with malignant disease. Cochrane Database Syst. Rev.3, CD003407 (2004).
   Google Scholar
• Ross S, Allen E, Henry D, Seaman C, Sercus B, Goodnough L. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther.28(6), 801–831 (2006).
   PubMed Web of Science ®Google Scholar
• Khuri F. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N. Engl. J. Med.356(24), 2445–2448 (2007).
   PubMed Web of Science ®Google Scholar
• Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj.19(9), 725–727 (2005).
   PubMed Web of Science ®Google Scholar
• Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression, and quality of life of mixed-site cancer patients and their partners. Psychooncology15(3), 259–267 (2006).
   Google Scholar
• Hanna A, Sledge G, Mayer ML et al. A Phase II study of methylphenidae for the treatment of fatigue. Support Care Cancer14(3), 210–215 (2006).
   PubMedGoogle Scholar
• Bruera E, Valero V, Driver L et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol.24, 2073–2078 (2006).
   PubMed Web of Science ®Google Scholar
• Fox S, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J. Nurs. Scholarsh.39(1), 61–67 (2007)
   PubMed Web of Science ®Google Scholar
• Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J. Neurooncol.57(1), 41–49 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Linzmayer L, Becherer A et al. Psychometric and quality of life assessment in long-term glioblastoma survivors. J. Neurooncol.63, 55–61 (2003).
   PubMed Web of Science ®Google Scholar
• Gottwald B, Wilde B, Mihaljlovic Z, Mehdorn HM. Evidence for distinct cognitive deficits after focal cerebellar lesions. J. Neurol. Neurosurg. Psychiatr.75, 1524–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Sherwood PR, Given BA, Given CW et al. Predictors of distress in caregivers of persons with a primary malignant brain tumor. Res. Nurs. Health29(2), 105–120 (2006).
   PubMed Web of Science ®Google Scholar
• Correa DD. Cognitive functions in brain tumor patients. Hematol. Oncol. Clin. North Am.20(6), 1363–1376 (2006).
   PubMed Web of Science ®Google Scholar
• Brown PD, Jensen AW, Felten SJ et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J. Clin. Oncol.24(34), 5427–5433 (2006).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J. Clin. Oncol.16(7), 2522–2527 (1998).
   PubMed Web of Science ®Google Scholar
• Mulhern R, Khan R, Kaplan S. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J. Clin. Oncol.22, 4795–4803 (2004)
   PubMed Web of Science ®Google Scholar
• Conklin H, Khan RB, Reddick WE et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J. Pediatr. Psychol. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Shaw E, Rosdhal R, D’Agostino RB et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J. Clin. Oncol.24, 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Butler JM, Rapp SR, Shaw EG. Managing the cognitive effects of brain tumor radiation therapy. Curr. Treat. Options Oncol.7(6), 517–523 (2006).
   PubMedGoogle Scholar
• Cohen M, Johnson J, Pazdur R. Food and Drug Administration Drug Approval Summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin. Cancer Res.11(19), 6767–6771 (2005).
   PubMed Web of Science ®Google Scholar
• Taphoorn M, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomized conrolled trial. Lancet Oncol.6, 937–944 (2005).
   PubMed Web of Science ®Google Scholar
• Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith T. Improving palliative and supportive care in cancer patients. Oncology19(10), 1365–1376; discussion 1377-8, 1381-2, 1384 passim (2005).
   PubMedGoogle Scholar
• Gilliam F. Optimizing health outcomes in active epilepsy. Neurology58(Suppl. 5), S9–S19 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Compostella A, Blatt V, Tosoni A. Glioblastoma in the elderly: current and future trends. Crit. Rev. Oncol. Hematol.60, 256–266 (2006).
   PubMedGoogle Scholar
• Noble SIR, Nelson A, Turner I, Finlay G. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. Br. Med. J.332, 577–580 (2006).
   PubMedGoogle Scholar